您当前所在的位置:首页 > 产品中心 > 产品信息
Methylphenidate_分子结构_CAS_113-45-1)
点击图片或这里关闭

Methylphenidate

产品号 DB00422 公司名称 DrugBank
CAS号 113-45-1 公司网站 http://www.ualberta.ca/
分子式 C14H19NO2 电 话 (780) 492-3111
分子量 233.30616 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 305

产品价格信息

请登录

产品别名

标题
Methylphenidate
IUPAC标准名
methyl 2-phenyl-2-(piperidin-2-yl)acetate
IUPAC传统名
methylphenidate
商标名
Centedrin
Ritalin SR
Metadate CD
PMS-Methylphenidate
Centredin
Methypatch
Metadate
Riphenidate
Ritalin hydrochloride
Ritalin LA
Concerta
Focalin XR
Methylphen
Ritalin-SR
Ritaline
Ritcher Works
Daytrana
Metadate ER
Methylin
Methylin ER
Methylofenidan
Methylphenidan
Plimasine
Ritalin
4311/B Ciba
Calocain
Centedein
Centedrine
Focalin
Meridil
别名
Methylphenidate HCl
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
d-methylphenidate HCl
Methyl phenidyl acetate
Methylphenidate hydrochloride
Metilfenidat hydrochloride
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
Phenidylate
methylphenidate

产品登记号

PubChem SID 46505929
CAS号 113-45-1
PubChem CID 4158

产品性质

疏水性(logP) 2.1
溶解度 1255mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine. [PubChem]
Indication For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
Pharmacology Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.
Toxicity Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)
Affected Organisms
Humans and other mammals
Biotransformation Hepatic, methylphenidate is metabolized primarily by de-esterification to ritalinic acid (α-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity.
Absorption Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)
Half Life 2.4 hours in children and 2.1 hours in adults
Protein Binding Low (approximately 15%)
References
Keating GM, McClellan K, Jarvis B: Methylphenidate (OROS formulation). CNS Drugs. 2001;15(6):495-500; discussion 501-3. [Pubmed]
Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98. [Pubmed]
Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93. [Pubmed]
Sharma RP, Javaid JI, Pandey GN, Easton M, Davis JM: Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. Psychiatry Res. 1990 Apr;32(1):9-17. [Pubmed]
Shults T, Kownacki AA, Woods WE, Valentine R, Dougherty J, Tobin T: Pharmacokinetics and behavioral effects of methylphenidate in Thoroughbred horses. Am J Vet Res. 1981 May;42(5):722-6. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

  • Keating GM, McClellan K, Jarvis B: Methylphenidate (OROS formulation). CNS Drugs. 2001;15(6):495-500; discussion 501-3. Pubmed
  • Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98. Pubmed
  • Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93. Pubmed
  • Sharma RP, Javaid JI, Pandey GN, Easton M, Davis JM: Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. Psychiatry Res. 1990 Apr;32(1):9-17. Pubmed
  • Shults T, Kownacki AA, Woods WE, Valentine R, Dougherty J, Tobin T: Pharmacokinetics and behavioral effects of methylphenidate in Thoroughbred horses. Am J Vet Res. 1981 May;42(5):722-6. Pubmed